Zacks Investment Research on MSN
BDX introduces BD Research Cloud 7.0 for advanced flow cytometry
Becton, Dickinson and Company BDX, popularly known as BD, recently announced the global commercial launch of BD Research ...
As the incidence of cancer rises around the world, the demand for faster, more precise diagnoses is also on the rise. This demand will only intensify over time, as the worldwide incidence of cancer is ...
BD is finalizing a February 5 spinoff, creating a $17.5B life sciences company with a $40B addressable market.
Extracellular vesicles can provide a wealth of information, but these intriguing messengers are notoriously difficult to detect. This could be about to change. Extracellular vesicles (EVs) are a ...
The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company ...
Zacks Investment Research on MSN
BD gets FDA 510(k) approval for EnCor EnCompass breast biopsy system
Becton, Dickinson and CompanyBDX, popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System. Anticipated to ...
Global Cell Analyzer Market OverviewThe global cell analyzer market is poised for strong expansion, with forecasts indicating a CAGR of nearly 8% from 2025 to 2030. This growth trajectory is driven by ...
All right. Great. Welcome to JPMorgan Healthcare Conference. I'm Casey Woodring from the Life Science Tools and Diagnostics team. Pleased to be joined by Waters' CEO, Udit Batra. Udit is going to go ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results